Impact of sublingual immunotherapy with dust mite drops on ECP, TARC, VCAM-1 inflammatory status in patients with allergic rhinitis.

IF 2.3 4区医学 Q3 IMMUNOLOGY

Immunotherapy Pub Date : 2026-07-01 Epub Date: 2026-08-04 DOI:10.1080/1750743X.2026.2704434

Bangyu Deng, Yunxia Zhao, Jisheng Liu

{"title":"Impact of sublingual immunotherapy with dust mite drops on ECP, TARC, VCAM-1 inflammatory status in patients with allergic rhinitis.","authors":"Bangyu Deng, Yunxia Zhao, Jisheng Liu","doi":"10.1080/1750743X.2026.2704434","DOIUrl":null,"url":null,"abstract":"Objective: To evaluate the effect of sublingual immunotherapy with dust mite drops on serum eosinophil cationic protein (ECP), thymus and activation-regulated chemokine (TARC), vascular cell adhesion molecule-1 (VCAM-1) levels and symptom improvement in allergic rhinitis (AR) patients.Methods: A prospective randomized controlled trial enrolled 300 AR patients sensitized to dust mites, randomly assigned to control group (conventional treatment, n = 150) and research group (conventional treatment plus sublingual dust mite drops, n = 150) for 6 months.Results: Compared with controls, the research group showed significantly greater reductions in interleukin-4 (IL-4), interleukin-17 (IL-17), ECP, TARC, VCAM-1, lower adverse reaction rates, improved pulmonary function including forced vital capacity (FVC), forced expiratory volume in the first second (FEV1), peak expiratory flow (PEF), FEV1/FVC ratio, and small airway function including maximal mid-expiratory flow (MMEF), expiratory flow rate at 50% of FVC (MEF50), expiratory flow rate at 25% of FVC (MEF25), as well as reduced symptom scores (all p < 0.05).Conclusion: Sublingual immunotherapy with Dust mite drops appears effective in suppressing systemic inflammation, minimizing treatment-related adverse events, enhancing both small airway and pulmonary function, and easing the clinical manifestations of allergic rhinitis.","PeriodicalId":13328,"journal":{"name":"Immunotherapy","volume":" ","pages":"813-823"},"PeriodicalIF":2.3000,"publicationDate":"2026-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13540133/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Immunotherapy","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/1750743X.2026.2704434","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2026/8/4 0:00:00","PubModel":"Epub","JCR":"Q3","JCRName":"IMMUNOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Objective: To evaluate the effect of sublingual immunotherapy with dust mite drops on serum eosinophil cationic protein (ECP), thymus and activation-regulated chemokine (TARC), vascular cell adhesion molecule-1 (VCAM-1) levels and symptom improvement in allergic rhinitis (AR) patients.

Methods: A prospective randomized controlled trial enrolled 300 AR patients sensitized to dust mites, randomly assigned to control group (conventional treatment, n = 150) and research group (conventional treatment plus sublingual dust mite drops, n = 150) for 6 months.

Results: Compared with controls, the research group showed significantly greater reductions in interleukin-4 (IL-4), interleukin-17 (IL-17), ECP, TARC, VCAM-1, lower adverse reaction rates, improved pulmonary function including forced vital capacity (FVC), forced expiratory volume in the first second (FEV1), peak expiratory flow (PEF), FEV1/FVC ratio, and small airway function including maximal mid-expiratory flow (MMEF), expiratory flow rate at 50% of FVC (MEF50), expiratory flow rate at 25% of FVC (MEF25), as well as reduced symptom scores (all p < 0.05).

Conclusion: Sublingual immunotherapy with Dust mite drops appears effective in suppressing systemic inflammation, minimizing treatment-related adverse events, enhancing both small airway and pulmonary function, and easing the clinical manifestations of allergic rhinitis.

查看原文本刊更多论文

尘螨滴剂舌下免疫治疗对变应性鼻炎患者ECP、TARC、VCAM-1炎症状态的影响

目的：探讨尘螨滴剂舌下免疫治疗对变应性鼻炎（AR）患者血清嗜酸性粒细胞阳离子蛋白（ECP）、胸腺及活化调节趋化因子（TARC）、血管细胞粘附分子-1 （VCAM-1）水平及症状改善的影响。方法：前瞻性随机对照试验，纳入300例对尘螨敏感的AR患者，随机分为对照组（常规治疗，150例）和研究组（常规治疗加舌下尘螨滴剂，150例），疗程6个月。结果:与对照组相比，研究组患者白细胞介素-4 （IL-4）、白细胞介素-17 （IL-17）、ECP、TARC、VCAM-1水平明显降低，不良反应发生率降低，肺功能包括用力肺活量（FVC）、第一秒用力呼气量（FEV1）、呼气峰流量（PEF）、FEV1/FVC比值改善，气道功能包括最大呼气中流量（MMEF）、50% FVC时呼气流量（MEF50）、结论：尘螨滴剂舌下免疫治疗可有效抑制全身炎症反应，减少治疗相关不良事件，增强小气道和肺功能，缓解变应性鼻炎的临床表现。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Immunotherapy 医学-免疫学

CiteScore

5.00

自引率

3.60%

发文量

113

审稿时长

6-12 weeks

期刊介绍： Many aspects of the immune system and mechanisms of immunomodulatory therapies remain to be elucidated in order to exploit fully the emerging opportunities. Those involved in the research and clinical applications of immunotherapy are challenged by the huge and intricate volumes of knowledge arising from this fast-evolving field. The journal Immunotherapy offers the scientific community an interdisciplinary forum, providing them with information on the most recent advances of various aspects of immunotherapies, in a concise format to aid navigation of this complex field. Immunotherapy delivers essential information in concise, at-a-glance article formats. Key advances in the field are reported and analyzed by international experts, providing an authoritative but accessible forum for this vitally important area of research. Unsolicited article proposals are welcomed and authors are required to comply fully with the journal''s Disclosure & Conflict of Interest Policy as well as major publishing guidelines, including ICMJE and GPP3.